Comparing Keytruda vs Tarceva
| Keytruda (pembrolizumab) | Tarceva (erlotinib) |
|
|---|
| Keytruda (pembrolizumab) | Tarceva (erlotinib) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including... View more |
Prescription only
Prescribed for Non Small Cell Lung Cancer, Pancreatic Cancer. Tarceva may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||
| More about Keytruda (pembrolizumab) | More about Tarceva (erlotinib) | ||||||||
| Ratings & Reviews | |||||||||
|
Keytruda has an average rating of 4.9 out of 10 from a total of 254 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 48% reported a negative effect. |
Tarceva has an average rating of 8.5 out of 10 from a total of 42 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 10% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Keytruda side effects |
View all Tarceva side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Keytruda prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
|
N/A |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
624 hours |
36.2 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 589 drugs are known to interact with Keytruda:
|
A total of 304 drugs are known to interact with Tarceva:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
N/A |
November 18, 2004 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
|
|||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.